Avantor, Inc. $AVTR Stock Position Trimmed by Royce & Associates LP

Royce & Associates LP decreased its position in Avantor, Inc. (NYSE:AVTR – Free Report) by 8.9% in the 3rd quarter, Holdings Channel reports. The fund owned 3,347,873 shares of the company’s stock after selling 328,211 shares during the period. Royce & Associates LP’s holdings in Avantor were worth $50,385,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Avantor during the second quarter valued at approximately $695,784,000. Barrow Hanley Mewhinney & Strauss LLC purchased a new position in shares of Avantor in the second quarter valued at $195,386,000. Bank of America Corp DE purchased a new position in shares of Avantor in the second quarter valued at $108,795,000. Engine Capital Management LP boosted its stake in shares of Avantor by 65.8% in the first quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock valued at $155,082,000 after purchasing an additional 7,853,018 shares during the period. Finally, Freestone Grove Partners LP acquired a new stake in Avantor during the 2nd quarter valued at $56,577,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Stock Down 0.5%

Shares of Avantor stock traded down $0.07 on Friday, hitting $15.54. 6,819,433 shares of the company’s stock traded hands, compared to its average volume of 10,681,926. The stock has a market cap of $10.53 billion, a P/E ratio of 31.09, a PEG ratio of 7.06 and a beta of 0.95. The company has a quick ratio of 1.27, a current ratio of 1.89 and a debt-to-equity ratio of 0.63. The firm’s 50-day moving average is $15.70 and its 200 day moving average is $11.42. Avantor, Inc. has a 52-week low of $7.26 and a 52-week high of $17.45.

Avantor (NYSE:AVTR – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.01. Avantor had a return on equity of 9.79% and a net margin of 5.08%. The firm had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period in the previous year, the company earned $0.22 earnings per share. Avantor’s quarterly revenue was up 4.6% on a year-over-year basis. Equities analysts anticipate that Avantor, Inc. will post 0.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

AVTR has been the topic of several analyst reports. Morgan Stanley lifted their price target on shares of Avantor from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 13th. Deutsche Bank reissued a “hold” rating and issued a $17.00 price objective on shares of Avantor in a research report on Thursday, October 29th. Royal Bank Of Canada raised their target price on Avantor from $14.00 to $17.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 28th. Wells Fargo & Company raised their target price on Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Finally, Stifel Nicolaus lifted their target price on Avantor from $15.00 to $18.00 and gave the stock a “hold” rating in a research report on Thursday, October 29th. Two investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Avantor currently has an average rating of “Hold” and a consensus target price of $14.77.

Check Out Our Latest Report on AVTR

Avantor Company Profile

(Free Report)

Avantor, Inc. is a global provider of products and services used in life sciences, advanced technology and applied materials. Its customers include biopharmaceutical and healthcare companies, laboratories, universities and manufacturers. The company supplies chemicals, reagents, laboratory consumables and equipment, as well as materials used in biopharmaceutical production. Avantor also provides services such as procurement, inventory management and support for laboratory and production operations.

Recommended Stories

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.